story of the week
Copanlisib Plus Rituximab vs Placebo Plus Rituximab in Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Copanlisib Plus Rituximab Versus Placebo Plus Rituximab in Patients With Relapsed Indolent Non-Hodgkin Lymphoma (CHRONOS-3): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
Lancet Oncol 2021 Apr 09;[EPub Ahead of Print], MJ Matasar, M Capra, M Özcan, F Lv, W Li, E Yañez, K Sapunarova, T Lin, J Jin, W Jurczak, A Hamed, MC Wang, R Baker, I Bondarenko, Q Zhang, J Feng, K Geissler, M Lazaroiu, G Saydam, Á Szomor, K Bouabdallah, R Galiulin, T Uchida, LM Soler, A Cao, F Hiemeyer, A Mehra, BH Childs, Y Shi, PL ZinzaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.